322results about "Luteinising hormone-releasing hormone" patented technology

Amphipathic lytic peptides are ideally suited to use in a ligand / cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid. The two components-the ligand and the lytic peptide-may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide / peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.

Methods and compositions comprising GnRH-I and GnRH-II, GnRH-I and GnRH-II antibodies, anti-receptor antibodies, polynucleotide constructs and GnRH-I and GnRH-II analogs for immune enhancement and suppression, prevention and treatment of diseases and conditions characterized by abnormal T-cell activity, treatment of viral and prion-related diseases, and treatment of T-cell related neoplastic diseases are disclosed.

Pharmaceutical compositions are provided for the treatment of steroid-dependent and other diseases. The compositions are solutions for subcutaneous or intramuscular injection, and the active agent is a GnRH antagonist peptide according to general formula (1): Ac-DNal-DCpa-DPal-Ser-Aph(X1)-DAph(X2)-Leu-Lys(iPr)-Pro-DAla-NH2 present at a concentration sufficient to from a gel following administration.

This invention describes a novel format of monomeric bispecific fusion protein with immune activating property for clinical therapies. A bispecific fusion protein includes a first targeting domain with a specificity for a first target of interest; a bridging domain derived from a constant region of a light chain or heavy chain of an immunoglobulin, which may be a human immunoglobulin; and a second targeting domain with a specificity for a second target of interest. The bispecific fusion protein may further include a linker fused to the N-terminus or the C-terminus of the bridging domain. The first targeting domain is fused to the bridging domain and the second targeting domain is fused to the bridging domain or the linker. The linker may include a GGGGS sequence. The first target of interest may be CD20, Her2 / neu, or EpCAM, and the second targeting domain is a T-lymphocyte activating domain.

LHRH analogues and LHRH antagonists for use in the treatment or prophylaxis of hormone-dependent cancers, in particular prostate cancer, prostate carcinoma and / or advanced prostate carcinoma, by administering an initial dose of an LHRH analogue over a first period sufficient to effect hormonal castration, then administering a maintenance dose of an LHRH antagonist over a second period, the dose being insufficient to achieve and / or maintain hormonal castration.

A sustained-release preparation which comprises a physiologically active peptide of general formulawherein X represents an acyl group;R1, R2 and R4 each represents an aromatic cyclic group;R3 represents a D-amino acid residue or a group of the formulawherein R3′ is a heterocyclic group;R5 represents a group of the formula —(CH2)n—R5′ wherein n is 2 or 3, and R5′ is an amino group which may optionally be substituted, an aromatic cyclic group or an O-glycosyl group;R6 represents a group of the formula —(CH2)n—R6′ wherein n is 2 or 3, and R6′ is an amino group which may optionally be substituted;R7 represents a D-amino acid residue or an azaglycyl residue; andQ represents hydrogen or a lower alkyl group, or a salt thereof and a biodegradable polymer having a terminal carboxyl group.The sustained-release preparation shows a constant release of the peptide over a long time and is substantially free from an initial burst.

The invention provides a solid-phase preparation method for buserelin. The method comprises the following steps of: 1) preparing a Fmoc-Pro-HMPB-MBHA resin with degree of substitution of between 0.15 and 0.80mmol / g from Fmoc-Pro-OH and a HMPB-MBHA resin with degree of substitution of between 0.2 and 0.9mmol / g by a solid-phase synthesis method; 2) gradually coupling remaining protected amino acid of the Fmoc-Pro-HMPB-MBHA resin according to a peptide sequence to obtain buserelin-HMPB-MBHA resin; 3) cracking the buserelin-HMPB-MBHA resin to obtain fully-protected peptide; and 4) performing ethyl amination, deprotection and purification on the obtained fully-protected peptide to obtain buserelin. The invention aims to provide a buserelin solid-phase synthesis method which has the advantages of high yield, low cost, mild reaction conditions, small environmental pollution and contribution to realizing industrialization.

The invention discloses a method for improving the stability of polypeptide active pharmaceutical ingredients. The polypeptide active pharmaceutical ingredients comprise but are not limited to bivalirudin, octreotide acetate, lanreotide acetate, eptifibatide or cetrorelix acetate, ganirelix acetate, degarelix, liraglutide, oxytocin, thymosin alpha1, leuprolide acetate, goserelin acetate, terlipressin or linaclotide. The method comprises the steps that after polypeptide drugs are salified, a polypeptide solution containing compensation ions is obtained, and a target polypeptide product is prepared through an ultralow temperature vacuum freeze-drying method. According to the method for improving the stability of the polypeptide active pharmaceutical ingredients, the problem that the polypeptide active pharmaceutical ingredients are prone to degradation after being placed for a long time is solved, the uniformity of the product is improved, and the drug risk is reduced.

The invention discloses a solid-phase synthesis method of degarelix. The solid-phase synthesis method of degarelix comprises the following steps: on the basis of taking Fmoc-amino resin as a solid-phase carrier, replacing orotic acid fragments connected with an alanine benzene ring in the fifth site and an amino in the fourth site with ivdde, and performing sequential condensation reaction from the end C to the end N so as to connect 10 protected amino acids, thereby obtaining a full-protective peptide resin; then removing the Fmoc protecting group of end N D-Nal, acetylating by using acetic anhydride and pyridine, replacing ivDde with Hor, cutting the peptide resin by using a splitting agent, and precipitating by using frozen diethyl ether to obtain crude peptide. Besides, the invention also relates to a method for synthesizing a raw material Fmoc-Aph(ivDde)-OH by use of ivDde-OH and Fmoc-Aph-OH. The solid-phase synthesis method of degarelix has the advantages that the ivDde is introduced to synthesize decapeptide firstly and then the Hor is used as a substitute to avoid a rearrangement side reaction; the solid-phase synthesis method is simple in process steps, easy to control, low in influence on a human body and the environment, high in yield, and suitable for large-scale production.

A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. A controlled release composition comprising (1) a physiologically active substance or salt thereof in an amount of about 14% (w / w) to about 24% (w / w) based on the total composition weight, (2) hydroxynaphthoic acid selected from the group consisting of 3-hydroxy-2-naphthoic acid and 1-hydroxy-2-naphthoic acid or salt thereof, and (3) a lactic acid polymer or salt thereof having a weight-average molecular weight of 15000 to 50000 in which the content of polymers having molecular weights of 5000 or less is about 5% by weight or less, wherein the molar ratio of said hydroxynaphthoic acid or salt thereof to said physiologically active substance or salt thereof is from 3:4 to 4:3.

Amphipathic lytic peptides are ideally suited to use in a ligand / cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in mammals in vivo. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) The two components-the ligand and the lytic peptide-may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide.

In a step-wise synthesis of degarelix comprising 0.3 % by weight or less of 4-([2-(5-hydantoyl)]acetylamino)-phenylalanine analog on (solid support)-NH2 a step comprises providing a solution of an amino acid or peptide of which the a-amino group is protected by Fmoc; contacting the support with the solution in the presence of reagent for forming a peptide bond between a carboxyl group of the amino acid or peptide and (solid support)-NH2; removing Fmoc by contacting the support with an organic base, in particular piperidine, in an organic solvent. Also disclosed is degarelix of high purity prepared by the method of the invention and the use of Fmoc in the synthesis of degarelix.

The invention provides an immunogenic composition comprising a GnRH multimer and an antigenic carrier, an immunogenic composition comprising a recombinant vector containing a nucleic acid molecule encoding a GnRH multimer and optionally an antigenic carrier, antibodies elicited by the immunogenic compositions, and methods of using the immunogenic compositions and antibodies for modifying sexual physiology and behavior, improving the organoleptic properties of meat, and treating androgen-dependent prostate tumors and GnRH-sensitive ovarian tumors.

The invention discloses a GnRH polypeptide-methotrexate conjugate shown as a formula in the specification, and the GnRH polypeptide-methotrexate conjugate can be prepared from GnRH polypeptide or analogs thereof and methotrexate or derivatives thereof. The invention also provides a preparation method of the GnRH polypeptide-methotrexate conjugate and application of the GnRH polypeptide-methotrexate conjugate to prepare antitumor medicines. The GnRH polypeptide-methotrexate conjugate is simple in preparation technology, high in yield and easy to purify, has good tumor targeting property on the aspect of resisting tumors, and is capable of centralizing a medicine at the tumor position.

The invention relates to the field of synthesis of medicines and discloses a method for synthesizing degarelix. The method for synthesizing the degarelix comprises the following steps: enabling D-alanine with a protective group coupled with an N end to carry out esterification reaction with amino resin with a protective group coupled with an amino in the presence of a condensation reagent and an activation reagent to obtain peptide resin 1; extending and coupling other protective amino acids one by one by starting from the peptide resin 1 according to a sequence from C end to N end of the amino acid sequence of the degarelix in the presence of the condensation reagent and the activation reagent, to obtain corresponding peptide resins after extending and coupling each time and finally obtain degarelix resin, then carrying out acidolysis to obtain a degarelix crude product, and purifying the degarelix crude product to obtain a degarelix pure product. By virtue of the method for synthesizing the degarelix, a proper synthesizing scheme is selected; the adaptive amino resin and an acidolysis solution are selected; the overall synthesis process is optimized; the purity of the degarelix is obviously improved; the degarelix has a relatively high total yield and is free of pollution to any environment.

The invention discloses a preparation method of cetrorelix. According to the preparation method, a Fmoc-Linker-amino resin is taken as the starting raw material, nine amino acids with Fmoc-protecting groups are orderly connected from the C terminal to the N terminal, and after the Fmoc-protecting groups are removed, Ac-D-2-Nal-OH is further connected to obtain an N-terminal acetylated peptide resin, namely an Ac-full-protected decapeptide resin. The peptide resin is cut by use of a cracking reagent, and the cutting fluid is precipitated by use of ice ether to obtain a cetrorelix crude peptide, and then the cetrorelix crude peptide is separated and purified by use of an HPLC preparative chromatographic column, and freeze-dried to obtain a cetrorelix trifluoroacetate or a cetrorelix acetate. According to the preparation method of the cetrorelix, the minimal protection principle is adopted, and the N-terminal acetylated amino acid Ac-D-2-Nal-OH is used for replacing Fmoc-D-2-Nal-OH in advance to avoid the side reaction of the acetic anhydride in an acetylation reagent to the D-Cit side chain carbamido; and as a result, the product purity is improved, the yield of the coarse peptide is high and large-scale industrial production can be realized favorably.

The invention relates to a goserelin acetate solid-phase synthesis method, which comprises the following steps: HBTU / DIPEA is employed as a condensation system, Fmoc-Ser-OH, Fmoc-Trp-OH are successively coupled; a whole-protection lysate with corresponding voluminal amount according to 10 times of resin weight is added, a carrier 2-CTC Resin in an intermediate is removed, all side chain protective groups are reserved; the whole-protection lysate is adjusted to slight alkaline by using DIPEA(N,N-diisopropylethylaine), semicarbazide hydrochloride and PyBop(1H-benzotriazole-1-oxygen tripyrrole alkyl hexafluorophosphate) (used for a coupling agent of peptide) are added in the whole-protection lysate for reaction coupling, a goserelin peptide solution with the side chain protective group is obtained; the lysate with 20% of TFA / DCM is added in a freezing ether for settling to obtain the white solid crude peptide; the white solid crude peptide is dried under vacuum for solving by methyl alcohol, ammonium formate and Pa / c are added for a hydrogenation reaction to remove the side chain protective group in a peptide sequence. According to the invention, side reaction phenomena can be avoided, target peptide purity is increased, yield is high, operation is convenient and feasible, the intermediate can be tracked and controlled, and the whole process is benefit for enlarged production.

The invention is directed to analogs of LHRH-II and, more generally, to analogs of the LHRH family in which modifications have been made that confer enhanced binding affinity for LHRH receptors and / or improved metabolic stability.The invention is further directed to methods of targeted therapy and targeted imaging in patients with sex-hormone-related cancers or other LHRH-mediated diseases.

When a new connection is set up between a mobile station and a cellular telecommunications network, the starting frame of the new connection is selected using a simple rule so that the starting times of the interleaving periods of all the presently active connections between the mobile station and the cellular network are periodically aligned, thereby substantially simplifying the handover process. In addition, the length of the interleaving period can be set such that the periodic alignment is more frequent.

The invention discloses a safe, high-efficiency degarelix synthesis method, particularly a preparation method for a degarelix. With amino resin as an initial resin carrier, the method disclosed by the invention sequentially connects corresponding Fmoc-amino acids in a degarelix sequence by solid-phase synthesis, wherein Ac-D-2Nal-OH is adopted as the last amino acid, and by condensation reaction and deprotection reaction, fully protected degarelix peptide resin is obtained; acidolysis segmentation and ether sedimentation are then carried out, so that crude degarelix peptide is obtained; by chromatographic purification, acetic acid salinization and freeze drying, the acetic acid degarelix is obtained. The preparation method chooses Oxyma as safe, high-efficiency coupling reagent in order to increase the safety of the process and reduce the byproducts of the process. The process can adopt not only solid-phase synthesis but also liquid-phase synthesis, the byproducts of the process are little, and separation and purification are easy. The purity of the obtained final acetic acid degarelix product is up to 99 percent, the yield is up to 61 percent, and the final acetic acid degarelix product has considerable economically applicable value and a broad application prospect.

The invention provides a purification method of ganirelix acetate. The purification method comprises the steps of (1) purification of ganirelix crude peptide, wherein octadecylsilane bonded silica is adopted as a fixed phase, perchlorate / phosphoric acid solution with certain concentration is taken as an A phase and acetonitrile is taken as a B phase, the ganirelix crude peptide is purified by a gradient-elution high performance liquid chromatography (HPLC) method; (2) salt conversion and purification, wherein the alkylsilane bonded silica is taken as the fixed phase, glacial acetic acid solution with a certain concentration is taken as the A phase and the acetonitrile is taken as the B phase, salt conversion and purification are carried out by adopting the gradient elution HPLC method, and the solution collected and subjected to freeze-drying to obtain the ganirelix acetate. The invention aims at providing the purification method of the ganirelix acetate with stable and controllable process, high yield, high purity, and wide practical value and application prospect.

Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.

The invention discloses a solid-phase synthesis method of cetrorelix. The method completely avoids toxic [D-Cit(Ac)]-cetrorelix impurities of D-citrulline side chain acetylation. According to the method, amino resin is used as an initial resin carrier, corresponding Fmoc-amino acids in a cetrorelix sequence are sequentially connected with the solid-phase synthesis method, and all-protected cetrorelix peptide resin is obtained through a condensation reaction and a deprotection reaction; then acidolysis cutting and sedimentation by the aid of diethyl ether are performed, and crude cetrorelix peptides are obtained; cetrorelix acetate is obtained through chromatographic purification, acetate conversion and freeze-drying. According to the method, Ac-D-2Nal-OH is selected as connection of the last amino acid, so that acetylation termination is avoided. Both a solid-phase synthesis technology and a liquid-phase synthesis technology can be adopted, few technological byproducts are produced, and separation and purification are easy. The purity of the finally obtained cetrorelix acetate product is up to 99%, the yield is up to 40%, and the method has the considerable economical application value and the broad application prospect.

The invention relates to the field of medicine synthesizing and discloses a method for synthesizing Degarelix. The method is characterized in that the synthesizing of the whole Degarelix is separated into two parts from the fifth amino acid position to the sixth amino acid position, appropriate protecting groups are used for parts of protecting amino acid, and the whole synthesizing process is completed by using specific acidulate agents. The method has the advantages that an appropriate synthesizing scheme is selected, the suitable protecting groups and acidulate agents are selected, the whole synthesizing process is optimized, the purity of the Degarelix is increased evidently, high total yield is achieved, and generation of toxic hydantoin degradation products is avoided.

The invention discloses a preparation method of cetrorelix. The method has the specific steps that: (A) AM resin is adopted as initial resin; according to cetrorelix main-chain peptide sequence, amino acids with N-terminal Fmoc protection and side-chain protection are coupled sequentially, wherein peptide sequence 6-site amino acid coupling adopts Fmoc-D-Orn(Dde)-OH; (B) when coupling is finished, Fmoc protecting group is removed, and an acetylation reaction is carried out on the N terminal; (C) a mixed solution with hydrazine hydrate and DMF with a volume ratio of 3:97 is used for removing D-ornithine side-chain Dde protecting group; tert-butyl isocyanate is added, such that D-ornithine side-chain in decapeptide resin is subjected to a modification reaction, and fully protected cetrorelix peptide resin is obtained; and (D) peptide resin is subjected to cracking, purification, desalination, and lyophilization, such that cetrorelix can be obtained. The content of a process impurity [D-Cit(Ac)<6>]-cetrorelix is less than 0.1%. The preparation process provided by the invention has the advantages of high product purity and low cost. The preparation method is suitable for large-scale cetrorelix production. With the process, the content of the impurity [D-Cit(Ac)<6>]-cetrorelix can be effectively controlled without influencing the yield of cetrorelix.

The invention relates to a solid-liquid phase synthesis method for alarelin acetate, and mainly solves the technical problems of low yield, high cost, severe reaction conditions and serious pollution existing in the conventional synthesis method. The solid-liquid phase synthesis method mainly comprises the synthesis steps of: (1) coupling each protective amino acid one by one by using a fluorenylmethoxycarbonyl solid phase synthesis method by taking proline-dichloro-trityl-chlorine resin as initial resin and synthesizing to obtain side chain fully protected peptide chain resin; (2) cutting the side chain fully protected peptide chain resin to obtain a fully protected peptide chain segment pGluP-9; (3) performing C-terminal ethylamination on the fully protected peptide chain segment pGluP-9 to obtain a fully protected segment of the alarelin acetate; and (4) cutting the fully protected segment of the alarelin acetate to remove a side chain protective group to obtain alarelin acetate rough product peptide. The solid-liquid phase synthesis method has the advantages of high large-scale production capacity, easy operation, stable process, low production cost and total yield of exceeding 40 percent.